Search
Now showing items 1-10 of 28
Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
(2015-1-1)
BACKGROUND: Due to the limitations of existing treatment options for Clostridium difficile infection (CDI), new therapies are needed.OBJECTIVE: To review the available data on fidaxomicin regarding chemistry, mechanisms ...
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
(2016-5-10)
Fosfomycin is a new agent to Canada approved for the treatment of acute uncomplicated cystitis (AUC) in adult women infected with susceptible isolates of E. coli and Enterococcus faecalis. We reviewed the literature regarding ...
Comparison of Community-Associated and Health Care-Associated Methicillin-Resistant Staphylococcus aureus in Canada: Results from CANWARD 2007
(2009-1-1)
BACKGROUND: Community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) differ from health care-associated
MRSA (HA-MRSA) in their genotypic and phenotypic characteristics.
The purpose of the present study ...
Prevalence and Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Isolated in Canadian Hospitals: Results from CANWARD 2007
(2009-1-1)
OBJECTIVE: The purpose of the present study was to determine the prevalence
and molecular epidemiology of extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae identified from Canadian hospitals
in 2007.
METHODS: ...
In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients in Canadian Hospitals in 2007
(2009-1-1)
BACKGROUND: In 2008, ceftobiprole was approved by Health
Canada for the treatment of patients with complicated skin and skin
structure infections including diabetic foot infections; approval of
ceftobiprole by the United ...
Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007)
(2009-1-1)
BACKGROUND: Canadian hospitals as well as hospitals worldwide
are increasingly faced with antibiotic-resistant pathogens, including
multidrug-resistant (MDR) strains.
OBJECTIVES: To assess the prevalence of pathogens, ...
Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa
(2009-1-1)
BACKGROUND: With a limited number of available antimicrobial
agents to treat Pseudomonas aeruginosa infections, the prevention of
emergence of antimicrobial resistance and its subsequent spread is
critical. In the present ...
Ciprofloxacin or Imipenem Use Correlates with Resistance in Pseudomonas aeruginosa
(1998-1-1)
OBJECTIVE: To investigate the relationship between ciprofloxacin or imipenem use and antimicrobial resistance in Pseudomonas aeruginosa.METHODS: A retrospective review of monthly antimicrobial susceptibility reports for ...
Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
(1998-1-1)
OBJECTIVE: To compare and contrast imipenem and meropenem in terms of in vitro activity, pharmacokinetics, clinical efficacy and adverse effects.DATA SELECTION: MEDLINE search from 1975 to 1997 and follow-up of references.DATA ...
The New Fluoroquinolones: A Critical Review
(1999-1-1)
OBJECTIVE: This paper reviews the literature available on the new fluoroquinolones – clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin and trovafloxacin – to compare these agents with ...